Over the past year or two, plan sponsors have likely noticed drugs treating rheumatoid arthritis (RA) suddenly appearing in their listing of top therapeutic classes…
The Canadian retirement system is unproductive and inefficient, but how do we tame this administrative beast without toppling the entire system? Taming it requires simplicity,…
How are Canadian pension funds using ETFs?
Age to retirement isn't a good measure of risk tolerance.
While Canadian plan sponsors are more likely to be subsidiaries of American companies, there are many Canadian companies with subsidiaries in the United States. For…
A guide for volatile times.
It’s gratifying to see that the era of data-driven preferred provider networks (PPNs) is now upon us. The opportunities for plan sponsors and pharmacy providers…
Ambachtsheer's proposed retirement income fix.
In January 2014, the Senate’s Standing Committee on Social Affairs, Science and Technology released its report on the off-label use of prescription drugs in Canada.…
Business is all about individual preference these days. Same goes for investments.
Potential conflicts of interest a huge concern in Part 1 of this series on PRPPs.
To expense or not expense? The markets will ultimately decide which is best.
With 2013 well and truly over, a number of us begin to prepare for committee meetings—if they haven’t already been held—to discuss performance. Supported by…